La Trobe
1199244_Gunjur,A_2022.pdf (1.43 MB)

'Know thyself'- host factors influencing cancer response to immune checkpoint inhibitors.

Download (1.43 MB)
journal contribution
posted on 2022-09-06, 01:31 authored by Ashray Gunjur, Andrea J Manrique-Rincón, Oliver Klein, Andreas BehrenAndreas Behren, Trevor D Lawley, Sarah J Welsh, David J Adams
Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard-of-care for the treatment of a wide variety of solid neoplasms. However, tumour responses remain unpredictable, experienced by only a minority of ICI recipients across malignancy types. Therefore, there is an urgent need for better predictive biomarkers to identify a priori the patients most likely to benefit from these therapies. Despite considerable efforts, only three such biomarkers are FDA-approved for clinical use, and all rely on the availability of tumour tissue for immunohistochemical staining or genomic assays. There is emerging evidence that host factors – for example, genetic, metabolic, and immune factors, as well as the composition of one's gut microbiota – influence the response of a patient's cancer to ICIs. Tantalisingly, some of these factors are modifiable, paving the way for co-therapies that may enhance the therapeutic index of these treatments. Herein, we review key host factors that are of potential biomarker value for response to ICI therapy, with a particular focus on the proposed mechanisms for these influences. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Funding

This work is supported by the Cancer Research UK Cambridge Centre (C9685/A25117). AG is supported by a Cancer Research UK Cambridge Centre clinical research training fellowship and a 2021 John Monash Scholarship. AJM-R is supported by Open Targets (OTAR2049). AB is the recipient of a Fellowship from the Victorian Government Department of Health and Human Services acting through the Victorian Cancer Agency. DJA is supported by Cancer Research UK (C20510/A21717) and the Wellcome Trust (206194/Z/17/Z). Figures were created using .

History

Publication Date

2022-07-01

Journal

Journal of Pathology

Volume

257

Issue

4

Pagination

13p. (p. 513-525)

Publisher

Wiley

ISSN

0022-3417

Rights Statement

© 2022 The Authors.The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Usage metrics

    Journal Articles

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC